

Supplementary Figures S1-S2




Figure S1. PRISMA flowchart for medication review in TAA. Pubmed database search was performed from 2010 to 2021 including the terms “thoracic aortic aneurysm” and “therapy” in Title/Abstract, resulting in 66 records. Case reports, studies not referring to medical management of TAA (e.g. focused on surgical procedures or surgical complications), and studies on AAA or Marfan syndrome were excluded.




Figure S2. (A–C) Pathway analysis reveals three main networks involved in TAA. (A) connective tissue disorders. (B) cellular growth and proliferation, and tissue development. (C) cellular movement and immune cell trafficking.

B




Figure S2. (A–C) Pathway analysis reveals three main networks involved in TAA. (A) connective tissue disorders. (B) cellular growth and proliferation, and tissue development. (C) cellular movement and immune cell trafficking.

C




Figure S2. (A–C) Pathway analysis reveals three main networks involved in TAA. (A) connective tissue disorders. (B) cellular growth and proliferation, and tissue development. (C) cellular movement and immune cell trafficking.